BioMarin Pharmaceuticals BMRN ALDURAZYME — Total revenues
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by BioMarin Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: BioMarin Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioMarin Pharmaceuticals's aldurazyme — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioMarin Pharmaceuticals's ALDURAZYME — total revenues?
- BioMarin Pharmaceuticals (BMRN) reported ALDURAZYME — total revenues of $36.74M in Q1 2026.
- How has BioMarin Pharmaceuticals's ALDURAZYME — total revenues changed year-over-year?
- BioMarin Pharmaceuticals's ALDURAZYME — total revenues decreased by 25.0% year-over-year, from $48.98M to $36.74M.
- What is the long-term trend for BioMarin Pharmaceuticals's ALDURAZYME — total revenues?
- Over 4 years (2021 to 2025), BioMarin Pharmaceuticals's ALDURAZYME — total revenues has grown at a 14.2% compound annual growth rate (CAGR), from $122.77M to $208.51M.
- What does ALDURAZYME — total revenues mean?
- The total sales revenue generated by a specific pharmaceutical product.
- How do you interpret ALDURAZYME — total revenues?
- An increase indicates growing market adoption or successful pricing strategies, while a decrease may signal increased competition, patent expiration, or market saturation.
- How does ALDURAZYME — total revenues compare across companies?
- Comparable to product-level revenue reporting in other biopharmaceutical companies, often benchmarked against therapeutic area peers.